These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2611821)

  • 1. Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds.
    Yew WW; Kwan SY; Ma WK; Lui KS; Aung MK
    Clin Ther; 1989; 11(6):775-85. PubMed ID: 2611821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria.
    Shen GH; Wu BD; Hu ST; Lin CF; Wu KM; Chen JH
    Int J Antimicrob Agents; 2010 Apr; 35(4):400-4. PubMed ID: 20138481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection.
    Yew WW; Kwan SY; Ma WK; Aung-khin M; Mok CK
    Chest; 1989 May; 95(5):1051-5. PubMed ID: 2707062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single daily-dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection.
    Yew WW; Kwan SY; Ma WK; Khin MA; Mok CK
    Chest; 1989 Nov; 96(5):1150-2. PubMed ID: 2805845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of amikacin, erythromycin and doxycyline against Mycobacterium chelonei and Mycobacterium fortuitum.
    Garcia-Rodriguez JA; Martin-Luengo F
    Tubercle; 1978 Dec; 59(4):277-80. PubMed ID: 726085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effect of cefoxitin and amikacin combination on M. fortuitum.
    Orefici G; Scopetti F
    Boll Ist Sieroter Milan; 1988; 67(2):97-104. PubMed ID: 3228501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
    Wallace RJ; Swenson JM; Silcox VA; Bullen MG
    J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.
    Dalovisio JR; Pankey GA
    J Infect Dis; 1978 Mar; 137(3):318-21. PubMed ID: 632627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antimicrobial susceptibility testing of rapidly growing mycobacteria using the tablet diffusion method: resistance pattern of Norwegian Mycobacterium fortuitum and Mycobacterium chelonae isolates.
    Hoel T; Casals JB; Eng J
    APMIS; 1993 Jan; 101(1):27-32. PubMed ID: 8457323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
    Shungu DL; Ponticas S; Gill CJ
    Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus.
    Miyasaka T; Kunishima H; Komatsu M; Tamai K; Mitsutake K; Kanemitsu K; Ohisa Y; Yanagisawa H; Kaku M
    Int J Antimicrob Agents; 2007 Sep; 30(3):255-8. PubMed ID: 17616451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of in vitro selected resistance of Pseudomonas aeruginosa to cefoperazone, ceftazidime, azthreonam and imipenem.
    Van der Auwera P; Husson M; Bulliard G
    Drugs Exp Clin Res; 1986; 12(11):871-83. PubMed ID: 3102194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.
    Wallace RJ; Bedsole G; Sumter G; Sanders CV; Steele LC; Brown BA; Smith J; Graham DR
    Antimicrob Agents Chemother; 1990 Jan; 34(1):65-70. PubMed ID: 2327761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.
    Wallace RJ; Dalovisio JR; Pankey GA
    Antimicrob Agents Chemother; 1979 Nov; 16(5):611-4. PubMed ID: 526002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].
    Dailloux M; Petitpain N; Henry C; Weber M
    Pathol Biol (Paris); 1989 May; 37(5):346-9. PubMed ID: 2780092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium fortuitum wound infection following laparoscopy.
    Sethi S; Sharma M; Ray P; Singh M; Gupta A
    Indian J Med Res; 2001 Mar; 113():83-4. PubMed ID: 11525156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of activities of amikacin and sulphamethoxazole against Mycobacterium avium-intracellulare.
    Yew WW; Tam CM; Chan CY; Li MS; Cheng AF
    Int J Clin Pharmacol Res; 1993; 13(2):65-8. PubMed ID: 8354590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.
    Dalovisio JR; Pankey GA; Wallace RJ; Jones DB
    Rev Infect Dis; 1981; 3(5):1068-74. PubMed ID: 7339806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.